Search Results

The Beyeonics™ Maverick system has been used in surgery for the first time to successfully give surgeons enhanced visual and operational capabilities during neurosurgical and orthopedic procedures.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the launch of MAVERICK.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that it has received clearance from the FDA for its investigational new drug application (IND) for Abivertinib (Fujovee™) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.

Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active bispecific T-cell engagers COBRA™ platform, specifically designed to target solid tumors Maverick’s lead candidate TAK-186 (formerly MVC-101), a conditionally active T-cell engager, is first in its class to enter the clinic with recent Phase 1/2 study initiation